Gary Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses how biosimilar rituximab may be used in cancer care.
Transcript
Well again that's yet to be seen. Of course we do have a biosimilar rituximab as you allude to. It’s now approved in the United States, and it’s actually been in Europe for a longer period of time, so we have some experience there, and in fact as last year's [American Society of Clinical Oncology, ASCO] meeting last June, a European group presented data on the early utilization of rituximab in patients with lymphoma in Europe.
What was interesting there, and I think we may see the same thing happen here in the United States, is the utilization of the biosimilar rituximab was more favorable in patients with less curable forms of lymphoma. In other words, the oncologist was willing to use these new agents in a situation where the goal wasn't necessarily long-term survival or cure. They reserved the originator, Rituxan, for use in patients with, for instance, diffuse large B-cell lymphoma where the goal of treatment is usually cure.
There’s some discrimination in the use of that, which is perhaps understandable because this is not just supportive care. This is the mainstay of treatment for these patients, and if you're treating for curative intent, do you really want to take any chances if you're not quite sure, or if you haven't used the drug before?
So you’re more likely to use it in solid tumors in patients with metastatic disease perhaps or lymphoma with the low-grade lymphomas where your goal is extending life but not so much the likelihood of curability.
That’s data from Europe, but my guess is we're going to see a similar kind of gradual intake and then over time broad utilization across the subtypes of lymphoma.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.